Scientific Program

OMICS Group Conferences
Accelerating Scientific Discovery

4th International Conference on
Vaccines & Vaccination

September 24-26, 2014 Valencia Convention Centre, Spain

Sponsors & Exhibitors

SANOFI PASTEUR · VACCINOGEN Turning Cancer On Itself™ · GenPhar · C.T.L. Cellular Technology Ltd.



Media Partners

absave · labsave · biosave · BioSpectrum · Conference locate.com · contract-biotechnology.com · Globalsave media group · HPV Today · iptechex · BioPharm Insight · MNT Medical News Today · Medical News Today · Pharma Mirror · PharmaVision · Technology Networks.com · Gov Events

"Organize your Events at OMICS Group Conferences"

Proposals are invited for organizing Symposia/Workshops at OMICS Group Conferences or OMICS Group will sponsor small events at your universities in related areas under the title of your own. These proposals can be sent to respective conference mail ids or to *symposia@omicsonline.org*

OMICS Group Conferences
5716 Corsa Ave., Suite 110, Westlake Los Angeles, CA 91362-7354, USA
Phone: +1-650-268-9744, Fax: +1-650-618-1414, Toll free: +1-800-216-6499
Email: *vaccines2014@omicsonline.net*

Day 1 September 24, 2014

08:30-09:00 Registrations

Auditorium 3A

09:00-09:30 **Opening Ceremony**

Keynote Forum

09:30-09:35 **Introduction**

09:35-10:00 **Ray Spier**
University of Surrey, UK

10:00-10:25 **Michael G Hanna**
Vaccinogen, Inc., USA

10:25-10:50 **Nikolai Petrovsky**
Flinders Medical Centre Research, Australia

Group Photo

Coffee Break 11:00-11:15 @ Auditorium 3 Foyer

Vaccine adjuvants

Session Chair: Nikolai Petrovsky, Flinders Medical Centre Research, Australia

11:15-11:35 **Inter-bilayer cross-linked multi-lamellar vesicles (ICMVs) for efficient co-delivery of antigen and adjuvant payloads**
Alan R Shaw, Vedantra Pharmaceuticals, USA

11:35-11:55 **Adjuvant-guidance of T cell responses**
Magdalena Tary-Lehmann, Cellular Technology Limited, USA

11:55-12:15 **Antibody targeting of human T cell CD27 identifies genes and pathways related to inflammation**
Venky Ramakrishna, Celldex Therapeutics, USA

12:15-12:35 **Evaluation of ZOSTAVAX® via the intradermal route using the MicronJet™**
Brian K. Meyer, Merck & Co., USA

12:35-12:55 **Universal influenza vaccines: Prevention of infection against matched and mismatched strains**
Harry Kleanthous, Sanofi-Pasteur, Inc., USA

12:55-13:15 **DNA vaccines which encode natural adjuvants are more effective than canonical DNA vaccines**
Eric James Gowans, The University of Adelaide, South Australia

Lunch Break 13:15-14:00 @ Multi Purpose Hall 2

14:00-14:20 **Immune memory resilience, a new way of evaluating adjuvants**
Jean-Pierre Y Scheerlinck, The University of Melbourne, Australia

14:20-14:40 **Novel lipid based adjuvants and delivery systems for induction of CD8 T cell immunity**
Lakshmi Krishnan, National Research Council-Human Health Therapeutics, Canada

14:40-15:00 **Establishment of lipid-based immunogens for the development of novel subunit vaccines**
Chih-Hsiang Leng, National Health Research Institutes, Taiwan

15:00-15:20 **Highly immunogenic C-terminal binding domain of *Clostridium difficile* toxin a stimulates dendritic cell maturation**
Pele Choi-Sing Chong, National Health Research Institutes, Taiwan

Coffee Break 15:20-15:35 @ Auditorium 3 Foyer

15:35-15:55 **The Cronobacter sakazakii ESP2949-1 phage induces dendritic cell maturation via activation of nuclear factor-κB and IL-12p40 in murine bone marrow**
Hyo-Ihl Chang, Korea University, Korea

15:55-16:15 **Nasal administration of antigens using maltodextrin nanoparticles: A mechanistic study**
Didier Betbeder, University of Luille2, France

16:15-16:35 **Stabilized liposomes carrying bee venom new formulation is the breakthrough of pain and anaphylaxis and death in mice under venom immunotherapy**
Maria Helena Bueno da Costa, Scientific Consultant, France

16:35-16:55 **Live vaccine for equine influenza on the base of cold-adapted recombinant strain A/HKOtar/6:2/2010**
Sandybayev Nurlan, Research Institute for Biological Safety Problems, Republic of Kazakhstan

16:55-17:15 **Polio outbreak in the Middle East: Update**
Randa Hamadeh, Ministry of Public Health, Lebanon

17:15-17:35 **Outer membrane vesicle of bacteria: Friend or Foe?**
Seyed Davar Siadat, Pasteur Institute of Iran, Iran

17:35-17:55 **Adjuvant properties of outer-membrane-vesicle in hepatitis B surface based vaccine**
Arfa Moshiri, Shahid Beheshti University of Medical Sciences, Iran

17:55-18:15 **Role of interferon gamma as immune adjuvant in *Labeor ohita***
Megha Kadam Bedekar, Central Institute of Fisheries Education, India

Panel Discussion 18:15-18:25

Breakout @ Committee Room 6-7

Biodefense vaccine

Session Chair: Leonard A Smith, United States Army Medical Research Institute of Infectious Diseases, USA

11:15-11:35 **Finding a safe, efficacious and stable vaccine in the ricin protein fold**
Leonard A Smith, United States Army Medical Research Institute of Infectious Diseases, USA

11:35-11:55 **A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation**
Connie S Schmaljohn, United States Army Medical Research Institute of Infectious Diseases, USA

11:55-12:15 **MVA-BN® (IMVANEX®/IMVAMUNE®): A non-replicating, new generation smallpox vaccine available for updating smallpox preparedness plans**
Nathaly Arndtz-Wiedemann, Bavarian Nordic GmbH, Germany

12:15-12:35 **A vaccine pipeline: Using phage display for identification of immunogenic proteins and generation of human antibodies for diagnostics and therapy**
Michael Hust, Technische Universität Braunschweig, Germany

Panel Discussion 12:35-12:45

Lunch Break 12:45-13:30 @ Multi Purpose Hall 2

Veterinary vaccines

Session Chair: Jean L Patterson, Texas Biomedical Research Institute, USA

13:30-13:50 **Quality and consistency of cell culture media with a highlight on FMDV**
Serge Ohreser, Merck Millipore, France

13:50-14:10 **Vaccine development at animal biosafety level four: Standards and challenges**
Jean L Patterson, Texas Biomedical Research Institute, USA

14:10-14:30 **Low dose antigen exposure in extreme early life promotes adaptive immune response in lambs and piglets**
Heather L Wilson, University of Saskatchewan, Canada

14:30-14:50 **Study immune correlates of vaccine-induced protective immunity against rotavirus infection and diarrhea using B cell deficient neonatal gnotobiotic pigs**
Lijuan Yuan, Virginia Polytechnic Institute and State University, USA

14:50-15:10 **Targeting aminopeptidase N on enterocytes rapidly induces an IgA response in a pig model**
Eric Cox, Ghent University, Belgium

15:10-15:30 **Use of ORF-1 product Rep in prevention and diagnosis of porcine circovirosis**
Silvia Pellicer, World Pathol, Spain

Coffee Break 15:30-15:45 @ Auditorium 3 Foyer

15:45-16:05 **Properties of ghost bacterial cells obtained by hybrid material with silver nanoparticles (PVA/ AgNps) as well as their opportunities for use in vaccine prophylactics**
Daniela Pencheva, Bul Bio - NCIPD Ltd., Bulgaria

16:05-16:25 **Imapct of three inactivated bovine viral diarrhoea (BVD) vaccines on bulk milk p80 (NS3) ELISA readings in commercial irish dairy herds**
Riona Sayers, Animal & Grassland Research and Innovation Center, Ireland

16:25-16:45 **Construction of Phix174 gene E mediated lysis system for generation of *Salmonella Enteritidis* ghost, and its evaluation as a vaccine candidate for the immunogenicity and protective efficacy against avian salmonellosis**
Chetan V Jawale, Chonbuk National University, Republic of Korea

16:45-17:05 **Use of viral interference against avian influenza and establishment of protection levels in field outbreaks in Mexico**
Inkar Castellanos, Viren SA de CV, Mexico

Panel Discussion 17:05-17:15

Day 2 September 25, 2014

Auditorium 3A

Keynote Forum

09:00-09:05 **Introduction**

09:05-09:30 **Geert Vanden Bossche**
UNIVAC LLC., Belgium

09:30-09:55 **Jeffrey Ulmer**
Novartis Vaccines & Diagnostics, USA

Group Photo

Therapeutic vaccines for chronic infecti

Session Chair: Jeffrey Ulmer, Novartis Vaccines & Diagnostics, USA

10:05-10:25 **Mimogen-a new strategy for post-exposure vaccine development**
Yuzhang Wu, Third Military Medical University, China

10:25-10:45 **Generation of robust immunity following DNA vaccine immunization enhanced by intradermal electroporation**
Kate E Broderick, Inovio Pharmaceuticals, USA

10:45-11:05	**M2SR, a robust flu vaccine with long-lasting, cross-protective immunity** **Pamuk Bilsel,** Flugen Inc., USA
	Coffee Break 11:05-11:20 @ Auditorium 3 Foyer
11:20-11:40	**In vivo electroporation for improvement of therapeutic DNA vaccine against chronic hepatitis B infection** **Lucyna Cova,** INSERM, France
11:40-12:00	**A Synthetic multi-antigen approach targeting *Plasmodium falciparum* malaria** **Bernadette Ferraro,** University of Pennsylvania, USA
12:00-12:20	**Pneumococcal infections and vaccination** **Birgitta Henriques-Normark,** Karolinska Institute, Sweden
12:20-12:40	**Heat shock protein complex vaccines against mucosal pathogenic bacteria** **Phil Sutton,** Murdoch Childrens Research Institute, Australia
12:40-13:00	**Upgrading the 100 year-old BCG vaccine** **Zakaria Hmama,** University of British Columbia, Canada
	Lunch Break 13:00-13:45 @ Multi Purpose Hall 2
13:45-14:05	**Immunization with neuraminidase deficient influenza virus is highly immunogenic and non-pathogenic to wild type and immunocompromised mice** **Alexandre M. Vieira Machado - Fiocruz,** Rene Rachou Research Center, Brazil
14:05-14:25	**Design and evaluation of a novel OspA-based vaccine for the prevention of Lyme borreliosis** **Andreas Meinke,** Valneva Austria GmbH, Austria
14:25-14:45	**Therapeutic vaccines for drug-resistant tuberculosis** **Tjip van der Werf,** University of Groningen, The Netherlands
14:45-15:05	**Vaccination in risk groups with special focus on non-responsiveness to routine vaccines** **Ursula Wiedermann,** Medical University of Vienna, Austria
15:05-15:25	**Post challenging effects of new formulation of leishmania major antigen in Balb/c mice** **Latifynia Afshineh,** Tehran University of Medical Sciences, Iran
	Coffee Break 15:25-15:40 @ Auditorium 3 Foyer
15:40-16:00	**Immunological studies on tetanus toxoid** **Rakesh Kumar,** Serum Institute of India Limited, India
16:00-16:20	**Process development and immunogenicity studies on a serogroup 'X' meningococcal polysaccharide conjugate vaccine** **Srinivas Reddy,** Serum Institute of India Ltd., India
16:20-16:40	**Self-adjuvanting promiscuous peptide of Mycobacterium tuberculosis augments polyfunctional Th17 cells and evokes better memory T cell response than BCG** **Javed N Agrewala,** CSIR - Institute of Microbial Technology, India
16:40-17:00	**Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected with *Mycobacterium tuberculosis*** **Xueqiong Wu,** the 309th Hospital of Chinese PLA, China
17:00-17:20	**Speciation of chromium in medicinal plants from selected farms in the vicinity of ferrochrome** **Isiaka Alade Owolabi,** Tshwane University of Technology, South Africa
	Panel Discussion 17:20-17:30
16:30-17:30	**Special Session for Students: Nikolai Petrovsky @ Community Hall 1-2** **Scientific writing, Journal review, Grant writing, Strategies for building a scientific career and Scientific careers outside of research**

Breakout @ Committee Room 6-7

Cancer vaccines

Session Chair: Michael G Hanna, Vaccinogen, Inc., USA

10:05-10:25	**From viruses to tumor associated antigen cancer vaccines** **Giulio Tarro,** Temple University Center for Biotechnology, USA
10:25-10:45	**Measles Virus vaccine infects tumor cells and induces dendritic cells (DC) maturation and tumor antigen cross-presentation** **Marc GREGOIRE,** Institut de Recherche en Sante Universite de Nantes, INSERM, France
10:45-11:05	**Personalized therapeutic cancer vaccine development to treat metastatic diseases** **Periasamy Selvaraj,** Emory University, USA
	Coffee Break 11:05-11:20 @ Auditorium 3 Foyer
11:20-11:40	**Teaching self-destructing *Salmonella* new tricks to fight cancer** **Wei Kong,** Arizona State University, USA
11:40-12:00	**DC targeting skin vaccines for improved cancer immunotherapy** **Yvette van Kooyk,** VU Unversity Medical Center, The Netherlands
12:00-12:20	**Acceptability of human papillomavirus vaccine: A survey among master of business administration students in KwaZulu-Natal, South Africa** **M E Hoque,** University of KwaZulu-Natal, South Africa
	Panel Discussion 12:20-12:30

AIDS/HIV vaccine

12:30-12:50	**Antigenicity, structure and immunogenicity of the HIV-1 trimeric envelope glycoprotein spike** **Richard T Wyatt,** The Scripps Research Institute La Jolla, USA
	Lunch Break 12:50-13:35 @ Multi Purpose Hall 2

13:35-13:55 **Application of neutralization fingerprints in delineating antibody recognition in HIV-1 sera and antibody epitope prediction**
Gwo-Yu Chuang, National Institutes of Health, USA

13:55-14:15 **The balance of cellular and humoral immunity determines the level of protection offered by an HIV vaccine in macaque models of HIV infection**
Timothy Fouts, Profectus BioSciences, Inc., USA

14:15-14:35 **VAC-3S vaccine, a novel approach to the therapeutic management of HIV Infection. Overview of phase I and phase II clinical vaccine development programs**
Raphael Ho Tsong Fang, InnaVirVax, France

14:35-14:55 **Characterization of a potent and broad neutralizing antibody that specifically recognizes a point-substitution in the 3S motif of the HIV-1 gp41 protein**
Patrice DEBRE, INSERM, France

14:55-15:15 **Glycosylation of envelope gp120 is affected by producer cell type and impacts HIV-1 recognition by virus-specific antibodies and cell infection**
Milan Raska, Palacky University, Czech Republic

Coffee Break 15:15-15:30 @ Auditorium 3 Foyer

15:30-15:50 **DNA vaccination against drug resistance in chronic viral infections, example of HIV-1**
Maria ISAGULIANTS, Karolinska Institutet, Sweden; Riga Stradins Univeristy, Latvia

15:50-16:10 **Evaluation of immune response in small animal models by in vivo imaging**
Stefan Petkov, Karolinska Institutet, Sweden

16:10-16:30 **Human clinical trial of SAV001 prophylactic HIV vaccine and a new strategy for the development of therapeutic HIV vaccine**
Chil-Yong Kang, The University of Western Ontario, Canadav

Panel Discussion 16:30-16:40

Vaccine antigen modeling

16:40-17:00 **Optimizing the delivery of novel immune potentiators within vaccine drug products**
Manmohan Singh, Novartis Vaccines, USA

17:00-17:20 **Natural killer cell subsets display helper and suppressor effects in modulating host viral responses *in vivo***
William J Murphy, UC Davis School of Medicine, USA

17:20-17:40 **Strategies of antigen retargeting for improvement of DNA vaccine performance**
Elizaveta Starodubova, Karolinska Institutet, Sweden

17:40-18:00 **Cellular vaccines in Listeriosis: Role of the *listeria* antigen GAPDH**
Carmen Alvarez-Dominguez, Instituto de Formacion e Investigacion Marques de Valdecilla, Spain

18:00-18:20 **Regulation of STING expression via the RIG-I dependent RNA sensing pathway**
Rongtuan Lin, McGill University, Canada

18:20-18:40 **Cell engineering and antibiotic-free selection for vaccinal antigens production in *E. coli*: The ultimate sophistication to combine safety and productivity**
Regis Sodoyer, Sanofi Pasteur, France

18:40-19:00 **Leishmania recombinant antigen modulates the macrophage effector functions synergizing anti-leishmanial effects of miltefosine to facilitate early clearance of intracellular parasites**
Sunil K Arora, PGIMER, India

Day 3 September 26, 2014

Auditorium 3A

Immuno-informatics in vaccine design

Session Chair: Malcolm E Thomas, Arbovax., Inc., USA

09:00-09:20 **Immunization and human rights**
Obradovic Zarema, University of Sarajevo, Bosnia and Herzegovina

09:20-09:40 **SIgN's clinical immunomonitoring platform for the assessment of immune responses in cohort studies and clinical trials**
Brian Abel, Singapore Immunology Network, Singapore

09:40-10:00 **Potent cellular and humoral immunogenicity of a pre-erythrocytic viral vectored malaria vaccine in African infants and children**
Katie Ewer, University of Oxford, UK

10:00-10:20 **The common computer-based influenza vaccination/epidemics surrveilance system: Challenges and opportunities for primary health care in EU countries**
Ljiljana Majnaric Trtrica, JJ Strossmayer University, Croatia

10:20-10:40 **The development of tuberculosis subunit vaccine EAMMH and regulation of vaccine induced immune memory by Rapamycin**
Bingdong Zhu, Lanzhou University, China

10:40-11:00 **Immunization programme in Indonesia: Overview- (Focusing on *Streptococcus Pneumonia* whole-cell vaccine)**
Julitasari Sundoro, Indonesian Technical Advisory Group on Immunization, Indonesia

Panel Discussion 11:00-11:10

Coffee Break 11:10-11:25 @ Auditorium 3 Foyer

Vaccine formulation issues

11:25-11:45 **Unique nanofabrication of antigens and adjuvants that effectively induces protective antibody and T cell responses**
Frank J Malinoski, Liquidia Technologies Inc., USA

11:45-12:05	**Development of a carbohydrate-based vaccine against meningococcal serogroup X infection** **Francesco Berti,** Novartis Vaccines, Italy
12:05-12:25	**Effect of the inclusion of "contemporary" *B. pertussis* strains in the vaccine composition on temporal trends in *B. pertussis* population** **Tatjana Pljesa,** Institute of Virology, Vaccines and Sera Torlak, Serbia
12:25-12:45	**Specificities of health economics in the area of vaccines evaluation** **Maarten J Postma,** University of Groningen, The Netherlands
12:45-13:05	**The effect of new leishmania vaccine against Th1, Th2 as well as increasing of spleen white pulp size in Bulb/c mice after repeated exposure** **Latifynia Afshineh,** Tehran University of Medical Sciences, Iran

Panel Discussion 13:05-13:15

Lunch Break 13:15-14:00 @ Multi Purpose Hall 2

Unconventional vaccines

14:00-14:20	**A novel approach to the development of arboviral vaccines for dengue and chikungunya virus** **Malcolm E Thomas,** Arbovax., Inc., USA
14:20-14:40	**Strategies toward developing a universal ExPEC vaccine capable of broad protection** **Melha Mellata,** Arizona State University, USA
14:40-15:00	**The vaxonella platform for oral recombinant vaccine delivery** **Rocky M Cranenburgh,** Prokarium Ltd., UK
15:00-15:20	**Oral vaccine platform elicits neutralizing antibody responses to influenza** **Sean Tucker,** Vaxart, Inc., USA
15:20-15:40	**A rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of influenza B globular head vaccines** **Langzhou Song,** VaxInnate Corporation, USA

Coffee Break 15:40-15:55 @ Auditorium 3 Foyer

15:55-16:15	**Responsibility: A "first person ethics" for vaccination** **Fermin J Gonzalez-Melado,** Pontifical Institute "John Paul II" for Studies on Marriage and Family, Spain
16:15-16:35	**Development of a truly improved whooping cough vaccine** **Marcel Thalen,** Iliad Biotechnologies, Scotland
16:35-16:55	**Translational development and preclinical efficacy of a multiantigen T cell epitope-enriched DNA vaccine against *Leishmaniasis*** **Christiane Juhls,** MOLOGEN AG, Germany
16:55-17:15	**Oral infections in Guinea Conakry** **Sylvain Haba,** Centre Des Soins Medico-Tradi-Spirituels Talithakoumi, Guinea Conakry

Panel Discussion 17:15-17:25

12:30-14:30
Poster Presentations @ Auditorium 3 Foyer
Day-2

VAC-001	**Using NYVAC vectors as vaccine candidates for Leishmaniasis** **Ernesto Mejias Perez,** Centro Nacional de Biotecnologia, Spain
VAC-002	**Enhancement of antigen-specific CD4 T cell response through spacer modification in vaccinia virus promoters** **Mauro Di Pilato,** Centro Nacional de Biotecnologia, Spain
VAC-003	**IL-34 suppresses Candida albicans induced TNF-a production by M1 macrophages through down-regulation of Dectin-1 and TLR2 expression** **Rong Xu,** Cardiff University, UK
VAC-004	**Protection of chickens against *Chlamydia psittaci* challenge by mucosal immunization with the major outer membrane protein** **Daisy Vanrompay,** Ghent University, Belgium
VAC-005	**The single intradermal cervical comparative testand Johne's disease ELISA diagnostics** **Aideen Kennedy,** Animal & Grassland Research and Innovation Centre, Ireland
VAC-006	**Antigen on nanoparticles enhances anti-tumor immune responses as well as humoral antibody responses *in vivo*** **Junichiro Mizuguchi,** Tokyo Medical University, Japan
VAC-007	**Hepatitis B immunizationstatus of a miscellaneous population of workers** **Frederic DESCHAMPS,** University Hospital of Reims, France
VAC-008	**Retinoic acid promotes long lasting mucosal and systemic immune responses after mucosal priming and systemic boosting in mice** **Silvia Vendetti,** Istituto Superiore di Sanita, Italy
VAC-009	**Experimental chagas disease: Vaccination with *Trypanosoma rangeli* modulate the innate immune response in mice challenged with *Trypanosoma cruzi*** **Beatriz Basso,** National University of Cordoba, Argentina
VAC-010	**Effect of preventive and therapeutic vaccination schedules with *Trypanosoma rangeli* against *Trypanosoma cruzi* infection in a mouse model of Chagas' disease** **Beatriz Basso,** National University of Cordoba, Argentina
VAC-011	**Generation of genetically inactivated *Salmonella Gallinarum* ghost and evaluation of its potential as an effective inactivated vaccine candidate against fowl typhoid** **Chetan V Jawale,** Chonbuk National University, Korea

VAC-012 **Construction of tightly regulated E-lysis cassette for production of genetically inactivated *Salmonella* Enteritidisghost**
Chetan V. Jawale, Chonbuk National University, Korea

VAC-013 **Increasing of alive plague vaccine efficiency**
Ponomaryova Tatyana, Kazakh Scientific Center of Quarantine and Zoonotic Diseases, Kazakhstan

VAC-014 **Double-blind randomized placebo-controlled trial to evaluate cell-mediated immunity and safety of the herpes zoster vaccine in elderly patients with diabetes**
Atsuko Hata, The Tazuke Kofukai Medical Research Institute, Japan

VAC-015 **Analysis of phage displayed antibody fragment - pros and cons of Phage ELISA and RISE methods**
Barbara Kalenik, Institute of Biochemistry and Biophysics Polish Academy of Sciences, Poland

VAC-016 **HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in Africa**
Athina KILPELAINEN, Karolinska Institutet, Sweden

VAC-017 **Retargeting of HIV reverse transcriptase to MHC class II processing improves its immunogenicity**
Anastasia Latanova, Karolinska Institutet, Sweden

VAC-018 **Lipopolysaccharide of *Coxiella burnetii*. A promising candidate molecule in a search for a new Q fever vaccine**
Rudolf Toman, Slovak Academy of Sciences, Slovak Republic

VAC-019 **Long-term immune response to Hepatitis B Virus (HBV) vaccine among type 1 diabetic students: Do they need a booster?**
Engy M. El-Ghitany, Alexandria University, Egypt

VAC-020 **Bivalent candidate vaccine against HCV and HIV-1: Construction and biological evaluation**
Mohammad Reza Aghasadeghi, Pasteur Institute of Iran, **Iran**

VAC-021 **An early report on a local project about primary health care to improve the communication and the compliance in the elderly for vaccinal campaigns against inluenza**
Filippo de Nicolellis, Primary Health Care, Italy

VAC-022 **Cyclic GMP-AMP has mucosal adjuvant activity in mice**
Christina Rueckert, Helmholtz Center for Infection Research, Germany

VAC-023 **Local and systemic antibody and cell-mediated immune response after vaccination and infection with porcine respiratory and reproduction system (PRRS) virus**
Miroslav Toman, Veterinary Research Institute, Czech Republic

VAC-024 **Using monoclonal antibodies to understand the molecular basis for the cross bactericidal activity of NHBA antigen**
Claudia Facciotti, Novartis, Italy

VAC-025 **Expression profile of cytokine transcripts and Cell mediated immune response in peripheral blood mononuclear cells of sheep following vaccination of pentavalent bluetongue vaccine**
Molalegne Bitew, Jimma University, Ethiopia

VAC-026 **In vitro molecular analysis of ribosomal initiation complexes assembly and RNA-protein interactions during the initiation of translation of a prototype Coxsackievirus B3 and a live-attenuated Sabin 3-like RNAs**
Amira SOUII, Universite de Tunis El Manar, Tunisia



Bookmark your dates

OMICS Group Conferences
Accelerating Scientific Discovery

Asia Pacific Global Summit and Expo on
Vaccines & Vaccination
June 01-03, 2015 Brisbane, Australia

OMICS Group Conferences
Accelerating Scientific Discovery

Euro Global Summit and Expo on
Vaccines & Vaccination
August 17-19, 2015 Birmingham, UK

OMICS Group Conferences
Accelerating Scientific Discovery

Indo Global Summit and Expo on
Vaccines & Vaccination
September 28-30, 2015 New Delhi, India

OMICS Group Conferences
Accelerating Scientific Discovery

Dubai Global Summit and Expo on
Vaccines & Vaccination
September 28-30, 2015 Dubai, UAE

OMICS Group Conferences
Accelerating Scientific Discovery

American Global Summit and Expo on
Vaccines & Vaccination
October 05-07, 2015 San Francisco, USA

OMICS Group Inc.
2360 Corporate Circle, Suite 400
Henderson, NV 89074-7722, USA
Ph: +1-888-843-8169
Fax: +1-650-618-1417
contact@omicsgroup.com

OMICS Publishing Group
5716 Corsa Ave., Suite 110, Westlake
Los Angeles, CA 91362-7354, USA
Ph: +1-650-268-9744
Fax: +1-650-618-1414
contact.americas@omicsonline.org

OMICS Group
SEZ Unit, Building No. 20, 9th Floor
APIIC Layout, HITEC City
Hyderabad-500081, Telangana, INDIA
Ph: 040-40131823, 040-47482222
contact.asiapacific@omicsonline.org

Toll free
USA & Canada: +1-800-216-6499
Australia: +1-800-651-097
Europe: 0805-080048